Agilent Technologies Inc. has announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types.

Tecan is excited to introduce its "We can with Tecan" competition, which will recognize the ground-breaking achievements in the field of NGS and reward two winners with their very own MagicPrep™ NGS instruments.

Avacta Group plc announces the opening of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.

Certis Oncology Solutions has announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Personalis, Inc., Cancer Research UK’s Cancer Research Horizons, University College London and the Francis Crick Institute have announced a collaboration to deploy a personalized liquid biopsy-based research assay, for the TRACERx study.

Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.

CureSearch for Children’s Cancer has announced that it will fund a Phase I clinical trial to bring new therapies to pediatric brain cancer patients, including those with limited or no treatment options.

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

Thermo Fisher Scientific and Arsenal Biosciences, Inc. have announced an update to their strategic collaboration to further the development of manufacturing processes for new cancer treatments.